EFFECTS OF ATORVASTATIN-FENOFIBRATE COMBINATION COMPARED TO ATORVASTATIN MONOTHERAPY ON LIPID PROFILE IN PATIENTS WITH COMBINED DYSLIPIDEMIA

被引：0
|
作者：
Derosa, G. [1 ]
Salvadeo, S. [1 ]
Ferrari, I. [1 ]
Cicero, A. [2 ]
机构：
[1] Univ Pavia, I-27100 Pavia, Italy
[2] Univ Bologna, Clin Med & Appl Biotechnol Dept, Bologna, Italy
来源：
ATHEROSCLEROSIS SUPPLEMENTS | 2009年 / 10卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Plasma LDL-C goal achievement with Atorvastatin Monotherapy versus Atorvastatin and Probucol combination therapy in patients with coronary atherosclerosis
    Binaykumar, Adhikari
    Zhang Sisi
    Meng, Xiaoping
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 64 (16) : C203 - C203
  • [42] Effects of atorvastatin and fenofibrate on postprandial lipemia in type 2 diabetic patients with hyperlipidemia
    Iovine, C
    Lilli, S
    Gentile, A
    Patti, L
    Di Marino, L
    Cipriano, P
    Riccardi, G
    Rivellese, AA
    ATHEROSCLEROSIS SUPPLEMENTS, 2005, 6 (01) : 110 - 110
  • [43] Atorvastatin/Fenofibrate 40/100 mg Fixed-Dose Combination Tablet (LCP-AtorFen 40/100 mg) Offers Improved Efficacy Over 40 mg Atorvastatin and Higher Dose 145 mg Fenofibrate in Patients with Dyslipidemia
    Davidson, Michael H.
    Rooney, Michael
    Drucker, Joan
    Griffin, H. E.
    Beckert, Michael
    CIRCULATION, 2008, 118 (18) : S1139 - S1139
  • [44] ATORVASTATIN EFFECTS ON LIPID PROFILE IN ApoE/LDLR-DEFICIENT MICE
    Slanarova, M.
    Vecerova, L.
    Strasky, Z.
    Ticha, A.
    Hyspler, R.
    Nachtigal, P.
    ATHEROSCLEROSIS SUPPLEMENTS, 2010, 11 (02) : 117 - 117
  • [45] EFFECT OF NEBIVOLOL OR NEBIVOLOL/HYDROCHLOROTHIAZIDE PLUS ATORVASTATIN ON GLYCEMIC PROFILE IN PATIENTS WITH HYPERTENSION AND DYSLIPIDEMIA
    Kei, A.
    Liberopoulos, E.
    Elisaf, M.
    ATHEROSCLEROSIS, 2015, 241 (01) : E127 - E127
  • [46] Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: assessment of clinical usefulness in CKD patients with atorvastatin (ASUCA) trial
    Genjiro Kimura
    Masato Kasahara
    Kenji Ueshima
    Sachiko Tanaka
    Shinji Yasuno
    Akira Fujimoto
    Toshiya Sato
    Miyuki Imamoto
    Shinji Kosugi
    Kazuwa Nakao
    Clinical and Experimental Nephrology, 2017, 21 : 417 - 424
  • [47] Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia
    Giral, P
    Bruckert, E
    Jacob, N
    Chapman, MJ
    Foglietti, MJ
    Turpin, G
    ATHEROSCLEROSIS, 2001, 154 (02) : 421 - 427
  • [48] Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: assessment of clinical usefulness in CKD patients with atorvastatin (ASUCA) trial
    Kimura, Genjiro
    Kasahara, Masato
    Ueshima, Kenji
    Tanaka, Sachiko
    Yasuno, Shinji
    Fujimoto, Akira
    Sato, Toshiya
    Imamoto, Miyuki
    Kosugi, Shinji
    Nakao, Kazuwa
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2017, 21 (03) : 417 - 424
  • [49] Antioxidant and lipid-regulating effects of probucol combined with atorvastatin in patients with acute coronary syndrome
    Guo, Yu-Song
    Wang, Cai-Xia
    Cao, Jian
    Gao, Jin-Liao
    Zou, Xiao
    Ren, Yi-Hong
    Fan, Li
    JOURNAL OF THORACIC DISEASE, 2015, 7 (03) : 368 - 375
  • [50] Hypolipidemic and pleiotropic effects of atorvastatin treatment in peripheral artery disease patients with dyslipidemia
    Buzin, A.
    Baranov, A.
    Obukhov, A.
    Sharkova, N.
    Bocharova, M.
    Puzenko, D.
    Obukhov, D.
    EUROPEAN HEART JOURNAL, 2008, 29 : 144 - 144
12345